Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Tempest Therapeutics Inc. buy Amped

Start price
€24.00
13.07.21 / 0%
Target price
-
13.07.22
Performance (%)
-5.85%
End price
€22.60
13.07.21
Summary
This prediction ended on 13.07.21 with a price of €22.60. With a performance of -5.85%, the BUY prediction for Tempest Therapeutics Inc. by Amped closed slightly in the red. This prediction was marked as speculative and is excluded from Amped's performance statistics.
Performance without dividends (%)
Name 1w 1m 1y
Tempest Therapeutics Inc. 3.758% 3.758% 81.164%
iShares Core DAX® -0.922% -1.078% 12.165%
iShares Nasdaq 100 0.371% -0.556% 38.622%
iShares Nikkei 225® 2.224% -2.825% 19.015%
iShares S&P 500 -0.026% -0.788% 28.485%

According to Amped what are the pros and cons of Tempest Therapeutics Inc. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Standard Investments for future growth
Good culture
Future proof or reliable business model
Sustainability is important
Cons
High valuation
Few uniques
Below average Marketposition
Little known brand

Comments by Amped for this prediction

In the thread Tempest Therapeutics Inc. diskutieren

Buy Tempest Therapeutics Inc.

In the thread Trading Tempest Therapeutics Inc.
Prediction Buy
Perf. (%) -5.85%
Target price
Change
Ends at 13.07.22

Buy beendet

Stopped prediction by Amped for Tempest Therapeutics Inc.

Tempest Therapeutics Inc.

Start price
Target price
Perf. (%)
€14.00
23.07.21
-
23.07.22
-84.43%
24.07.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Standard Investments for future growth
High valuation
Tempest Therapeutics Inc.

Start price
Target price
Perf. (%)
€22.60
13.07.21
-
13.07.22
-38.05%
23.07.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Standard Investments for future growth
High valuation